Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of MN-166 (Ibudilast) ER vs IR in Healthy Volunteers
NCT04054206Phase 1Completed
- Sponsor
- MediciNova, Inc.
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibudilast in multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), glioblastoma (GBM) and 2 more (6 arms), sponsored by MediciNova, Inc. Primary endpoints: Pharmacokinetic profile of ER and IR formulations in single-dose administration at 168 hours and Pharmacokinetic profile of ER and IR formulations in single-dose administration under fed or fasting states at 168 hours. Started Jun 2019; status: completed.
02
Drugs
ibudilast
03
Conditions
multiple sclerosis (MS)amyotrophic lateral sclerosis (ALS)glioblastoma (GBM)alcohol use disorder (AUD)substance use disorder (SUD)
Beyond the preview
Go deeper on NCT04054206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054206.